Alpha-1 Antitrypsin Deficiency — Early Panacinar Emphysema MCQ — NEET PG Practice Question | NEETPGAI
Alpha-1 Antitrypsin Deficiency — Early Panacinar Emphysema
medium
stethoscope Medicine
A 38-year-old never-smoker presents with exertional dyspnea and chronic cough. Spirometry shows FEV1 52% predicted with FEV1/FVC 0.55, TLC 128%, and severely reduced DLCO (38%). Serum alpha-1 antitrypsin is 28 mg/dL (normal 150–350 mg/dL) and genotyping confirms PiZZ phenotype. HRCT demonstrates basal-predominant panacinar emphysema with lower-lobe bullae. Which of the following management approaches, marked **C** in the diagram, represents the disease-modifying intervention most strongly supported by evidence in alpha-1 antitrypsin deficiency?
A. Inhaled corticosteroid monotherapy
B. Long-term azithromycin monotherapy
C. Intravenous alpha-1 antitrypsin augmentation therapy plus smoking cessation counseling
D. Lung volume reduction surgery as first-line intervention
Explanation
Why Intravenous alpha-1 antitrypsin augmentation therapy plus smoking cessation counseling is right
The RAPID trial (Lancet 2015) demonstrated that intravenous augmentation therapy with pooled plasma-derived human alpha-1 antitrypsin (60 mg/kg weekly) slows the rate of lung density loss on HRCT in patients with documented severe deficiency (serum level <57 mg/dL) and FEV1 30–65% predicted. Combined with absolute smoking cessation—which is the single most impactful intervention (smoking reduces life expectancy by ~25 years in PiZZ individuals)—this represents the only disease-modifying approach that addresses the underlying pathophysiology: restoring serum A1AT levels to provide protection against neutrophil elastase-mediated lung destruction. The ATS/ERS 2024 Standards recommend augmentation therapy as a cornerstone of management in eligible patients with severe deficiency and moderate-to-severe airflow obstruction.
Why each distractor is wrong
Inhaled corticosteroid monotherapy: ICS are used for exacerbation management in COPD but do not address the fundamental deficiency of alpha-1 antitrypsin and do not slow disease progression in AATD. They are adjunctive, not disease-modifying.
Lung volume reduction surgery as first-line intervention: LVR is generally contraindicated in alpha-1 antitrypsin deficiency because the emphysema is basal-predominant and panacinar (not upper-lobe centrilobular), making the anatomic distribution unsuitable for surgery. Durability of benefit is poor in AATD, and early transplant referral is preferred when FEV1 falls below 25–35%.
Long-term azithromycin monotherapy: Azithromycin may be considered as an anti-inflammatory add-on for frequent exacerbators in COPD but is not disease-modifying in AATD and does not replace augmentation therapy or smoking cessation as first-line interventions.
High-YieldNEET PG
In alpha-1 antitrypsin deficiency with FEV1 30–65% predicted and serum level <57 mg/dL, intravenous augmentation therapy + smoking cessation is the evidence-based disease-modifying combination; LVR is contraindicated due to basal-predominant panacinar distribution.
